<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28611098</article-id><article-id pub-id-type="pmc">5669172</article-id><article-id pub-id-type="doi">10.1161/JAHA.117.005562</article-id><article-id pub-id-type="publisher-id">JAH32244</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Interventional Cardiology</subject></subj-group></subj-group></article-categories><title-group><article-title>Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2&#x02010;Hour Infusion in High&#x02010;Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention</article-title><alt-title alt-title-type="left-running-head">Marian et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah32244-cr-0001" contrib-type="author" corresp="yes"><name><surname>Marian</surname><given-names>Moazez J.</given-names></name><degrees>PharmD, PhD</degrees><address><email>mjmarian@uab.edu</email></address><xref ref-type="aff" rid="jah32244-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32244-cr-0002" contrib-type="author"><name><surname>Alli</surname><given-names>Oluseun</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32244-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32244-cr-0003" contrib-type="author"><name><surname>Al Solaiman</surname><given-names>Firas</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32244-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32244-cr-0004" contrib-type="author"><name><surname>Brott</surname><given-names>Brigitta C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32244-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32244-cr-0005" contrib-type="author"><name><surname>Sasse</surname><given-names>Mark</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32244-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32244-cr-0006" contrib-type="author"><name><surname>Leesar</surname><given-names>Tara</given-names></name><degrees>BA</degrees><xref ref-type="aff" rid="jah32244-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32244-cr-0007" contrib-type="author"><name><surname>Prabhu</surname><given-names>Sumanth D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah32244-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah32244-cr-0008" contrib-type="author" corresp="yes"><name><surname>Leesar</surname><given-names>Massoud A.</given-names></name><degrees>MD</degrees><address><email>mleesar@uab.edu</email></address><xref ref-type="aff" rid="jah32244-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah32244-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Division of Cardiology</named-content>
<institution>University of Alabama at Birmingham</institution>
<named-content content-type="country-part">AL</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Moazez J. Marian, PharmD, PhD, UAB Thrombosis Research Lab, 1900 University BLVD, THB&#x02010;3rd floor, Birmingham, AL 35294. E&#x02010;mail: <email>mjmarian@uab.edu</email> and Massoud A. Leesar, MD, UAB Heart and Vascular Center, University of Alabama at Birmingham, 510 20th St S, FOT: 920, Birmingham, AL 35294. E&#x02010;mail: <email>mleesar@uab.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2017</year></pub-date><volume>6</volume><issue>6</issue><issue-id pub-id-type="doi">10.1002/jah3.2017.6.issue-6</issue-id><elocation-id>e005562</elocation-id><history><date date-type="received"><day>11</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-6-e005562.pdf"/><abstract id="jah32244-abs-0001"><sec id="jah32244-sec-0001"><title>Background</title><p>In patients with non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation acute coronary syndromes, inhibition of platelet aggregation (<styled-content style="fixed-case">IPA</styled-content>) with a potent P2Y<sub>12</sub> inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein <styled-content style="fixed-case">II</styled-content>b/<styled-content style="fixed-case">III</styled-content>a inhibitors are still needed. Ticagrelor and eptifibatide bolus only may maximally inhibit platelet aggregation and decrease bleeding, but <styled-content style="fixed-case">IPA</styled-content> with ticagrelor and eptifibatide bolus versus 2&#x02010;hour infusion is unknown.</p></sec><sec id="jah32244-sec-0002"><title>Methods and Results</title><p>A total of 70 P2Y<sub>12</sub>&#x02010;na&#x000ef;ve patients, with high&#x02010;risk non&#x02010;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation acute coronary syndromes, were randomized to ticagrelor and eptifibatide bolus (group 1) versus ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion (group 2). Levels of <styled-content style="fixed-case">IPA</styled-content> with <styled-content style="fixed-case">ADP</styled-content>, thrombin receptor&#x02010;activating peptide, collagen, and high on&#x02010;treatment platelet reactivity were measured by light transmission aggregometry at baseline and at 2, 6, and 24 hours after percutaneous coronary intervention in both groups. The primary end point, <styled-content style="fixed-case">IPA</styled-content> with <styled-content style="fixed-case">ADP</styled-content> 20&#x000a0;&#x003bc;mol/L at 2&#x000a0;hours, was 99.59&#x000b1;0.43% in group 1 versus 99.88&#x000b1;1.0% in group 2 (<italic>P</italic>&#x0003c;0.001 for noninferiority). High on&#x02010;treatment platelet reactivity with <styled-content style="fixed-case">ADP</styled-content> was zero at 2, 6, and 24 hours in both groups. <styled-content style="fixed-case">IPA</styled-content> levels with <styled-content style="fixed-case">ADP</styled-content>, thrombin receptor&#x02010;activating peptide, and collagen were significantly higher at 2 and 6 hours than at 24 hours in both groups. Periprocedural myocardial infarction was not significantly different between the groups. Hemoglobin level was significantly less at 24 hours versus baseline in group 2 (13.35&#x000b1;1.8&#x000a0;versus 12.38&#x000b1;1.8&#x000a0;g/dL, respectively; <italic>P</italic>&#x0003c;0.01).</p></sec><sec id="jah32244-sec-0003"><title>Conclusions</title><p>Ticagrelor and eptifibatide bolus maximally inhibited platelet aggregation at 2 hours, which was associated with no significant hemoglobin drop after percutaneous coronary intervention. This obviates the need for eptifibatide 2&#x02010;hour infusion and might decrease bleeding complications.</p></sec><sec id="jah32244-sec-0004"><title>Clinical Trial Registration</title><p>
<styled-content style="fixed-case">URL</styled-content>: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</ext-link>. Unique identifier: <styled-content style="fixed-case">NCT</styled-content>01919723.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah32244-kwd-0001">antiplatelet therapy</kwd><kwd id="jah32244-kwd-0002">eptifibatide</kwd><kwd id="jah32244-kwd-0003">inhibition of platelet aggregation</kwd><kwd id="jah32244-kwd-0004">ticagrelor</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Catheter-Based Coronary and Valvular Interventions</kwd><kwd>Pharmacology</kwd><kwd>Revascularization</kwd></kwd-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="4"/><page-count count="9"/><word-count count="6197"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah32244</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.1 mode:remove_FC converted:27.10.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah32244-cit-1001">(<source>J Am Heart Assoc</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e005562</elocation-id> DOI: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.117.005562">10.1161/JAHA.117.005562</ext-link>.)<pub-id pub-id-type="pmid">28611098</pub-id></mixed-citation>
</p></notes></front><body><p>
<boxed-text position="anchor" content-type="box" id="jah32244-blkfxd-0001" orientation="portrait"><sec id="jah32244-sec-0006"><title>Clinical Perspective</title><sec id="jah32244-sec-0007"><title>What is New?</title><p>
<list list-type="bullet" id="jah32244-list-0001"><list-item><p>Ticagrelor and eptifibatide bolus maximally IPA at 2 hours and obviates the need for eptifibatide 2&#x02010;hour infusion.</p></list-item><list-item><p>Platelet reactivity was below the cut point for ischemic risk throughout the 24&#x02010;hour period with ticagrelor and eptifibatide bolus.</p></list-item></list>
</p></sec><sec id="jah32244-sec-0008"><title>What are the Clinical Implications?</title><p>
<list list-type="bullet" id="jah32244-list-0002"><list-item><p>Current guidelines recommend a glycoprotein inhibitor infusion for 12 to 18&#x000a0;hours in high&#x02010;risk ACS patients, which increases the risk of bleeding.</p></list-item><list-item><p>The combination of ticagrelor and eptifibatide bolus only is likely to reduce the risk of bleeding in high&#x02010;risk ACS patients.</p></list-item><list-item><p>The absence of high platelet reactivity with the use of the combination of ticagrelor and eptifibatide bolus only is likely to reduce event rates.</p></list-item></list>
</p></sec></sec></boxed-text>
</p><sec id="jah32244-sec-0009"><title>Introduction</title><p>It has been demonstrated that the level of inhibition of platelet aggregation (IPA) is an independent predictor for the risk of adverse events after percutaneous coronary intervention (PCI).<xref rid="jah32244-bib-0001" ref-type="ref">1</xref> A recent pharmacodynamic (PD) study<xref rid="jah32244-bib-0002" ref-type="ref">2</xref> showed that IPA with ticagrelor alone was inferior to tirofiban infusion at 2 hours in patients with non&#x02010;ST&#x02010;segment elevation acute coronary syndromes (NSTE&#x02010;ACS). Furthermore, another recent PD study<xref rid="jah32244-bib-0003" ref-type="ref">3</xref> showed that the rate of high on&#x02010;treatment platelet reactivity (HPR) was still high at 2 hours in patients with unstable angina treated with ticagrelor alone. Likewise, a study showed<xref rid="jah32244-bib-0004" ref-type="ref">4</xref> that HPR was observed in a significant number of ACS patients (25.2%) who were treated with a loading dose of prasugrel at the time of PCI. The above series indicate that even fast&#x02010;acting P2Y<sub>12</sub> inhibitors, such as ticagrelor, or prasugrel, do not achieve maximal platelet inhibition after 2 hours of loading, the time frame in which patients undergo PCI. Furthermore, the rate of HPR was still high at 2 hours, suggesting that a glycoprotein IIb/IIIa receptor inhibitor (GPI) is needed to achieve maximal platelet inhibition.</p><p>Current guidelines<xref rid="jah32244-bib-0005" ref-type="ref">5</xref> and package labeling recommend a GPI (eg, eptifibatide infusion for 18&#x02013;24&#x02010;hours or tirofiban infusion for 12&#x02013;18&#x02010;hours) in patients with high&#x02010;risk NSTE&#x02010;ACS undergoing PCI. Despite the well&#x02010;established anti&#x02010;ischemic effect of GPI, an extended infusion of GPI was associated with increased risk of bleeding and mortality.<xref rid="jah32244-bib-0006" ref-type="ref">6</xref> On the other hand, a number of series reported that the rate of bleeding significantly decreased with a bolus or short infusion of GPI.<xref rid="jah32244-bib-0007" ref-type="ref">7</xref>, <xref rid="jah32244-bib-0008" ref-type="ref">8</xref> Ticagrelor and eptifibatide bolus, as compared with ticagrelor and eptifibatide 2&#x02010;hour infusion, might maximally inhibit platelet aggregation and reduce the risk of bleeding. However, IPA with ticagrelor and eptifibatide bolus versus 2&#x02010;hour infusion has not been studied. We, thus, compared IPA with ticagrelor and eptifibatide bolus versus ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion in patients with high&#x02010;risk NSTE&#x02010;ACS undergoing early PCI. We also compared the incidence of HPR, periprocedural myocardial infarction (PMI), hemoglobin/hematocrit levels post&#x02010;PCI, and cardiac events at 1&#x02010;year between the 2 groups.</p></sec><sec id="jah32244-sec-0010"><title>Methods</title><sec id="jah32244-sec-0011"><title>Patient Population</title><p>This was a prospective, randomized, single blind study in P2Y<sub>12</sub>&#x02010;na&#x000ef;ve patients with NSTE&#x02010;ACS. Patients were included in the study if they met the following criteria: angina at rest or recurrent angina associated with high&#x02010;risk features including elevated cardiac troponin I levels above the upper limit of normal and/or ST&#x02010;segment depression of at least 0.1&#x000a0;mV, and a coronary stenosis requiring PCI before randomization. Patients with the following criteria were excluded from the study: upstream use of P2Y<sub>12</sub>, inhibitors, or GPI; left main coronary artery stenosis; cardiogenic shock; thrombocytopenia with platelet count &#x0003c;100&#x000a0;000; severe hepatic impairment; surgery less than 4&#x000a0;weeks; concomitant therapy with strong cytochrome P&#x02010;450 3A inhibitors; and a need for oral anticoagulant therapy. The institutional review board approved the study and written informed consent was obtained from all patients.</p></sec><sec id="jah32244-sec-0012"><title>Study Design and Randomization</title><p>The study design is shown in Figure&#x000a0;<xref rid="jah32244-fig-0001" ref-type="fig">1</xref>. Eligible patients who were seen in the emergency room or admitted to the hospital with NSTE&#x02010;ACS underwent cardiac catheterization on the same day. After performing cardiac catheterization, eligible patients were randomized if there was a stenosis in the culprit vessel requiring PCI. Randomization was computer generated and was placed in sealed envelopes. Intravenous heparin (60&#x000a0;units/kg) or bivalirudin was administered to the eligible patients before PCI. Patients were randomized 1:1 to group 1 versus group 2. The baseline blood sample was withdrawn for light transmission aggregometry (LTA), and then the study medications (ticagrelor and eptifibatide bolus or 2&#x02010;hour infusion) were administered just before PCI. In group 1, ticagrelor (180&#x000a0;mg) and eptifibatide bolus (2 intravenous boluses were administered 10&#x000a0;minutes apart at a dose of 180 &#x003bc;g/kg; the first bolus was administered just before PCI). In group 2, ticagrelor (180&#x000a0;mg) and an eptifibatide bolus 180 &#x003bc;g/kg and a 2&#x02010;&#x003bc;g/kg per minute infusion for 2 hours were administered before PCI followed by a second eptifibatide bolus 180 &#x003bc;g/kg 10&#x000a0;minutes later. The maintenance dose of ticagrelor (90&#x000a0;mg twice a day) was started after drawing the last blood sample for PD study at 24&#x000a0;hours. Blood samples for troponin assay were collected at baseline and at 8 and 24&#x000a0;hours post&#x02010;PCI.</p><fig fig-type="Figure" xml:lang="en" id="jah32244-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Patient flow and study design. A, demonstrates the number of patients screened and randomized to 2 groups; (B) shows the study design and sampling schedule. Light transmission aggregometry (<styled-content style="fixed-case">LTA</styled-content>) was performed at baseline (before administration of ticagrelor and eptifibatide bolus or 2&#x02010;hour infusion) and at 2, 6, and 24&#x000a0;hours using <styled-content style="fixed-case">ADP</styled-content>, thrombin receptor activating peptide (<styled-content style="fixed-case">TRAP</styled-content>), and collagen after the administration of the study drug. Ticagrelor and eptifibatide bolus or infusion were administrated just before percutaneous coronary intervention (<styled-content style="fixed-case">PCI</styled-content>).</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-6-e005562-g001"/></fig></sec><sec id="jah32244-sec-0013"><title>Platelet Function Testing Using LTA</title><p>The design of the study is demonstrated in Figure&#x000a0;<xref rid="jah32244-fig-0001" ref-type="fig">1</xref>. After randomization, blood samples were collected at baseline (before administration of ticagrelor and eptifibatide) and at 2, 6, and 24&#x000a0;hours from the time of administration of eptifibatide and ticagrelor.</p><p>LTA was performed as previously reported.<xref rid="jah32244-bib-0009" ref-type="ref">9</xref> Briefly, blood samples were collected in 3.8% sodium citrate tubes. Platelet aggregation was tested using the turbidimetric method in a 2&#x02010;channel aggregometer (Chronlog Optical Aggregometer [model 490&#x02010;4D]; Chrono&#x02010;log Corporation, Havertown, PA). The following agonists were used for platelet stimulation: ADP (5 and 20&#x000a0;&#x003bc;mol/L); thrombin receptor&#x02010;activating peptide (TRAP; 10 and 20&#x000a0;&#x003bc;mol/L); and collagen 2&#x000a0;&#x003bc;g/&#x003bc;L. Briefly, platelet&#x02010;rich plasma was stimulated by adding an agonist to the cuvette in the aggregometer, and platelet aggregation was recorded as aggregation curves after the addition of each agonist for 6&#x000a0;minutes. The maximal extent of aggregation was expressed as the percent change in light transmittance from the baseline. Each measurement was performed in duplicate, and the average of the 2 measurements was recorded. Percent IPA (%IPA) was calculated as follows: %IPA=100%&#x000d7;(PAt&#x02212;PAb)/PAb, where PAb is platelet aggregation at baseline, and PAt is platelet aggregation after treatment with ticagrelor and eptifibatide.</p></sec><sec id="jah32244-sec-0014"><title>Study End Points and Definitions</title><p>The primary end point of the study was IPA stimulated with ADP 20&#x000a0;&#x003bc;mol/L at 2&#x000a0;hours. The secondary end points were as follows: HPR was defined as platelet aggregation &#x0003e;46% or &#x0003e;59% in response to ADP 5&#x000a0;&#x003bc;mol/L or ADP 20&#x000a0;&#x003bc;mol/L, respectively, as previously reported<xref rid="jah32244-bib-0010" ref-type="ref">10</xref>; PMI was defined as an increase in troponin I values &#x0003e;5&#x000d7;99th percentile the upper limit of normal in patients with normal baseline value on admission, or a rise of troponin I values &#x0003e;20% after PCI if the baseline value was elevated<xref rid="jah32244-bib-0011" ref-type="ref">11</xref>; the hemoglobin levels after PCI as compared with baseline in each group; and bleeding complication was classified according to the Bleeding Academic Research Consortium, as previously reported.<xref rid="jah32244-bib-0012" ref-type="ref">12</xref> The composite of major adverse events (death, myocardial infarction, stent thrombosis, and revascularization) was assessed at follow&#x02010;up.</p></sec><sec id="jah32244-sec-0015"><title>Clinical Follow&#x02010;up</title><p>Post&#x02010;PCI, patients were scheduled for follow&#x02010;up at 1&#x000a0;month and every 6&#x000a0;months thereafter. Major adverse cardiovascular events, including myocardial infarction, stent thrombosis, and&#x000a0;target vessel revascularization, were recorded during follow&#x02010;up.</p></sec><sec id="jah32244-sec-0016"><title>Sample&#x02010;Size Calculation and Statistical Analysis</title><p>The sample size of the study was determined based on noninferiority analysis that IPA after treatment with ticagrelor and eptifibatide bolus (group 1) stimulated with ADP 20&#x000a0;&#x003bc;mol/L would be noninferior to that of ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion (group 2). Because there are no previous data on IPA with ticagrelor and eptifibatide bolus or infusion, we estimated that IPA with ADP 20&#x000a0;&#x003bc;mol/L would be 88% in group 1 and 95% in group 2 at 2 hours, as previously reported.<xref rid="jah32244-bib-0002" ref-type="ref">2</xref> Assuming a noninferiority margin of 10%,<xref rid="jah32244-bib-0002" ref-type="ref">2</xref> 66 patients were required to meet the primary end point with a power of 80%. Considering a 5% dropout rate, we randomized 70 patients equally distributed between the 2 groups. We used a 1&#x02010;sided <italic>t</italic> test to calculate the noninferiority <italic>P</italic> value.</p><p>Continuous variables are shown as mean&#x000b1;SD and were compared by using the unpaired Student <italic>t</italic> test, and the chi&#x02010;square test was used to compare categorical variable between the groups. An ANCOVA with a general linear model was used to compare IPA levels between the groups, which were adjusted for baseline value of platelet aggregation, as previously reported.<xref rid="jah32244-bib-0013" ref-type="ref">13</xref> IPA levels at 2&#x02010;, 6&#x02010;, and 24&#x02010;hour time points within the groups were compared using one&#x02010;way ANOVA with Bonferroni correction for multiple testing. Statistical analysis was performed using SPSS software (version 22.0; SPSS Inc, Chicago, IL).</p></sec></sec><sec id="jah32244-sec-0017"><title>Results</title><sec id="jah32244-sec-0018"><title>Patient Characteristics</title><p>Between May 2014 and January 2015, 178 patients with NSTE&#x02010;ACS were screened; of these, 70 who met inclusion and exclusion criteria were enrolled in the study and randomized equally to 2 groups: group 1 (ticagrelor+eptifibatide bolus=35 patients) and group 2 (ticagrelor+eptifibatide bolus with 2&#x02010;hour infusion=35 patients). In 4 patients, 2 patients in each group, PD analysis could not be performed because blood samples hemolyzed. Therefore, PD analysis was performed in 66 patients (ticagrelor+eptifibatide bolus=33 patients; group 1) and (ticagrelor+eptifibatide bolus plus 2 infusion=33 patients; group 2). The baseline characteristics of the patients were similar between the groups (Table&#x000a0;<xref rid="jah32244-tbl-0001" ref-type="table-wrap">1</xref>). There were no significant differences between the groups with respect to positive troponin or ST&#x02010;segment depression (Table&#x000a0;<xref rid="jah32244-tbl-0001" ref-type="table-wrap">1</xref>).</p><table-wrap id="jah32244-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and Baseline Characteristics of Patients</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor+Eptifibatide Bolus (n=35) Group 1</th><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor+Eptifibatide Bolus and Infusion (n=35) Group 2</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">63&#x000b1;9</td><td align="left" rowspan="1" colspan="1">64&#x000b1;14</td><td align="left" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, male, n (%)</td><td align="left" rowspan="1" colspan="1">18 (51)</td><td align="left" rowspan="1" colspan="1">21 (60)</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="left" rowspan="1" colspan="1">6 (17)</td><td align="left" rowspan="1" colspan="1">8 (23)</td><td align="left" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension, n (%)</td><td align="left" rowspan="1" colspan="1">23 (66)</td><td align="left" rowspan="1" colspan="1">26 (74)</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, n (%)</td><td align="left" rowspan="1" colspan="1">13 (37)</td><td align="left" rowspan="1" colspan="1">12 (34)</td><td align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidemia, n (%)</td><td align="left" rowspan="1" colspan="1">17 (48)</td><td align="left" rowspan="1" colspan="1">20 (57)</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Peripheral vascular disease, n (%)</td><td align="left" rowspan="1" colspan="1">11 (31)</td><td align="left" rowspan="1" colspan="1">9 (26)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic renal failure</td><td align="left" rowspan="1" colspan="1">3 (8)</td><td align="left" rowspan="1" colspan="1">4 (11)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG</td><td align="left" rowspan="1" colspan="1">6 (17)</td><td align="left" rowspan="1" colspan="1">8 (23)</td><td align="left" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac troponin I level &#x02265;0.04&#x000a0;&#x003bc;g/mL, n (%)</td><td align="left" rowspan="1" colspan="1">25 (71)</td><td align="left" rowspan="1" colspan="1">23 (66)</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">ST&#x02010;segment depression on admission, n (%)</td><td align="left" rowspan="1" colspan="1">23 (66)</td><td align="left" rowspan="1" colspan="1">27 (77)</td><td align="left" rowspan="1" colspan="1">0.39</td></tr></tbody></table><table-wrap-foot><fn id="jah32244-note-0001"><p>CABG indicates coronary artery bypass graft.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32244-sec-0019"><title>Procedural Characteristics of Patients</title><p>The procedural characteristics of the patients are displayed in Table&#x000a0;<xref rid="jah32244-tbl-0002" ref-type="table-wrap">2</xref>. There were no significant differences between group 1 (ticagrelor and eptifibatide bolus) and group 2 (ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion) with respect to stent diameter, stent length, number of stents, postdilation balloon diameter, and postdilation balloon pressure. PCI was successfully performed in all, except in 1 patient randomized to group 2, in whom the lesion could not be crossed with a guidewire because of vessel tortuosity. The median times from hospital admission to PCI were not significantly different between group 1 versus group 2 (7&#x000a0;versus 6&#x000a0;hours, respectively; Table&#x000a0;<xref rid="jah32244-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="jah32244-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Procedural Characteristics of Patients</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor+Eptifibatide Bolus (n=35) Group 1</th><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor+Eptifibatide Bolus and Infusion (n=35) Group 2</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Coronary lesion</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Left main</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Left anterior descending, n</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Left circumflex, n</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Right, n</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stent diameter, mm</td><td align="left" rowspan="1" colspan="1">3.12&#x000b1;0.39</td><td align="left" rowspan="1" colspan="1">3.13&#x000b1;0.49</td><td align="left" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Total stent length, mm</td><td align="left" rowspan="1" colspan="1">26.9&#x000b1;15.2</td><td align="left" rowspan="1" colspan="1">25.1&#x000b1;11.5</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">No. of stents</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;0.60</td><td align="left" rowspan="1" colspan="1">1.2&#x000b1;0.48</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Drug&#x02010;eluting stents, %</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Postdilation balloon diameter, mm</td><td align="left" rowspan="1" colspan="1">3.5&#x000b1;0.67</td><td align="left" rowspan="1" colspan="1">3.5&#x000b1;0.65</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Postdilation balloon length, mm</td><td align="left" rowspan="1" colspan="1">14.3&#x000b1;3.1</td><td align="left" rowspan="1" colspan="1">13.2&#x000b1;2.3</td><td align="left" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Postdilation inflation pressure, atm</td><td align="left" rowspan="1" colspan="1">17.1&#x000b1;1.74</td><td align="left" rowspan="1" colspan="1">17.03&#x000b1;1.78</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">Heparin, %</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Bivalirudin, %</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">PCI, %</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Median time to PCI, IQR (h)</td><td align="left" rowspan="1" colspan="1">7 (5.25&#x02013;9.00)</td><td align="left" rowspan="1" colspan="1">6 (4&#x02013;8)</td><td align="left" rowspan="1" colspan="1">0.46</td></tr></tbody></table><table-wrap-foot><fn id="jah32244-note-0002"><p>IQR indicates interquartile range; PCI, percutaneous intervention.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah32244-sec-0020"><title>Assessment of Platelet Aggregation by LTA</title><p>Ticagrelor strongly inhibits the P2Y<sub>12</sub> receptor, and its efficacy was tested by ADP. Eptifibatide strongly inhibits GP IIb/IIIa receptors, and its efficacy was assessed by TRAP. As shown in Figure&#x000a0;<xref rid="jah32244-fig-0002" ref-type="fig">2</xref>, the baseline values of platelet aggregation (PA) with ADP 20&#x000a0;&#x003bc;mol/L and TRAP 20&#x000a0;&#x003bc;mol/L were not significantly different between the groups. In group 1, after administration of ticagrelor and eptifibatide bolus (T+E bolus), and in group 2 after ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion (T+E bolus with 2&#x02010;hours infusion), ADP&#x02010; and TRAP&#x02010;induced PA significantly decreased at 2, 6, and 24&#x000a0;hours as compared with their baseline values. Both ADP&#x02010; and TRAP&#x02010;induced PA values were significantly lower at 2 and 6&#x000a0;hours as compared with 24&#x000a0;hours. TRAP (20&#x000a0;&#x003bc;mol/L)&#x02010;induced PA was significantly higher in group 1 than in group 2 at 6&#x000a0;hours.</p><fig fig-type="Figure" xml:lang="en" id="jah32244-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Platelet aggregation (<styled-content style="fixed-case">PA</styled-content>) by light transmission aggregometry (<styled-content style="fixed-case">LTA</styled-content>). At baseline and at 2, 6, and 24&#x000a0;hours after treatment, gray bars represent <styled-content style="fixed-case">PA</styled-content> with <styled-content style="fixed-case">ADP</styled-content> 20&#x000a0;&#x003bc;mol/L in the ticagrelor and eptifibatide group (group 1, T+E); red bars represent <styled-content style="fixed-case">PA</styled-content> with <styled-content style="fixed-case">ADP</styled-content> 20&#x000a0;&#x003bc;mol/L in the ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion group (group 2, T+E bolus and 2&#x02010;hour infusion); green bars, <styled-content style="fixed-case">PA</styled-content> with thrombin receptor&#x02010;activating peptide (<styled-content style="fixed-case">TRAP</styled-content>) 20&#x000a0;&#x003bc;mol/L in the ticagrelor and eptifibatide group (group 1, T+E); and yellow bars, <styled-content style="fixed-case">PA</styled-content> with <styled-content style="fixed-case">TRAP</styled-content> 20&#x000a0;&#x003bc;mol/L in the ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion group (group 2, T+E bolus and 2&#x02010;hour infusion). <styled-content style="fixed-case">PA</styled-content> with <styled-content style="fixed-case">ADP</styled-content> 20&#x000a0;&#x003bc;mol/L or <styled-content style="fixed-case">TRAP</styled-content> 20&#x000a0;&#x003bc;mol/L was significantly higher at baseline than that at 2, 6, and 24&#x000a0;hours. <styled-content style="fixed-case">PA</styled-content> with <styled-content style="fixed-case">ADP</styled-content> or <styled-content style="fixed-case">TRAP</styled-content> was significantly lower at 2 and 6&#x000a0;hours than that at 24&#x000a0;hours.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-6-e005562-g002"/></fig></sec><sec id="jah32244-sec-0021"><title>Assessment of Inhibition of PA by LTA</title><p>The primary end point of the study, IPA levels at 2&#x000a0;hours after platelet stimulation with ADP 20&#x000a0;&#x003bc;mol/L, were similar in both groups (99.59&#x000b1;0.43% in group 1 versus 99.88&#x000b1;1.0% in group 2; mean difference=0.29%; upper bound of 95% CI, 0.71%; <italic>P</italic>&#x0003c;0.001 for noninferiority).</p><p>IPA levels after stimulation with ADP 5&#x000a0;&#x003bc;mol/L and ADP 20&#x000a0;&#x003bc;mol/L were not significantly different between the groups at 2 and 6&#x000a0;hours (Figure&#x000a0;<xref rid="jah32244-fig-0003" ref-type="fig">3</xref>A and <xref rid="jah32244-fig-0003" ref-type="fig">3</xref>B; Table&#x000a0;<xref rid="jah32244-tbl-0003" ref-type="table-wrap">3</xref>). IPA levels with ADP 5&#x000a0;&#x003bc;mol/L and ADP 20&#x000a0;&#x003bc;mol/L in groups 1 and 2 were significantly lower at 24&#x000a0;hours than at 2 and 6&#x000a0;hours (Figure&#x000a0;<xref rid="jah32244-fig-0003" ref-type="fig">3</xref>A and <xref rid="jah32244-fig-0003" ref-type="fig">3</xref>B; Table&#x000a0;<xref rid="jah32244-tbl-0003" ref-type="table-wrap">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah32244-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Inhibition of platelet aggregation (<styled-content style="fixed-case">IPA</styled-content>) with <styled-content style="fixed-case">ADP</styled-content>. A, <styled-content style="fixed-case">IPA</styled-content> stimulated with <styled-content style="fixed-case">ADP</styled-content> 5&#x000a0;&#x003bc;mol/L after treatment with ticagrelor and eptifibatide (T+E bolus) vs ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion (T+E bolus and 2&#x02010;hour infusion). B, <styled-content style="fixed-case">IPA</styled-content> stimulated with <styled-content style="fixed-case">ADP</styled-content> 20&#x000a0;&#x003bc;mol/L after treatment with ticagrelor and eptifibatide (T+E) bolus vs ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion (T+E bolus and 2&#x02010;hour infusion). In both groups (A and B), <styled-content style="fixed-case">IPA</styled-content> levels were significantly higher at 2 and 6&#x000a0;hours than 24&#x000a0;hours.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-6-e005562-g003"/></fig><table-wrap id="jah32244-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Inhibition of Platelet Reactivity</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor+Eptifibatide Bolus (n=33) Group 1 (%)</th><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor+Eptifibatide Bolus and Infusion (n=33) Group 2 (%)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">%IPA (ADP 20&#x000a0;&#x003bc;mol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x000a0;h</td><td align="left" rowspan="1" colspan="1">99.59&#x000b1;0.43</td><td align="left" rowspan="1" colspan="1">99.88&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6&#x000a0;h</td><td align="left" rowspan="1" colspan="1">98.4&#x000b1;4.4</td><td align="left" rowspan="1" colspan="1">99.31&#x000b1;2.9</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x000a0;h</td><td align="left" rowspan="1" colspan="1">55.7&#x000b1;23</td><td align="left" rowspan="1" colspan="1">59.4&#x000b1;27</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" colspan="4" rowspan="1">%IPA (ADP 5&#x000a0;&#x003bc;mol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x000a0;h</td><td align="left" rowspan="1" colspan="1">99.9&#x000b1;0.90</td><td align="left" rowspan="1" colspan="1">99.9&#x000b1;0.25</td><td align="left" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6&#x000a0;h</td><td align="left" rowspan="1" colspan="1">99.1&#x000b1;2.4</td><td align="left" rowspan="1" colspan="1">99.5&#x000b1;1.9</td><td align="left" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x000a0;h</td><td align="left" rowspan="1" colspan="1">66.27&#x000b1;17.6</td><td align="left" rowspan="1" colspan="1">68.4&#x000b1;22.3</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" colspan="4" rowspan="1">%IPA (TRAP 20&#x000a0;&#x003bc;mol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x000a0;h</td><td align="left" rowspan="1" colspan="1">88.9&#x000b1;8.1</td><td align="left" rowspan="1" colspan="1">92&#x000b1;5.5</td><td align="left" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6&#x000a0;h</td><td align="left" rowspan="1" colspan="1">74. 4&#x000b1;17.5</td><td align="left" rowspan="1" colspan="1">87.4&#x000b1;13.5</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x000a0;h</td><td align="left" rowspan="1" colspan="1">21.12&#x000b1;19.5</td><td align="left" rowspan="1" colspan="1">27.8&#x000b1;34.2</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" colspan="4" rowspan="1">%IPA (TRAP 10&#x000a0;&#x003bc;mol/L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x000a0;h</td><td align="left" rowspan="1" colspan="1">96.6&#x000b1;4.9</td><td align="left" rowspan="1" colspan="1">97.5&#x000b1;4.6</td><td align="left" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6&#x000a0;h</td><td align="left" rowspan="1" colspan="1">86.4&#x000b1;16.4</td><td align="left" rowspan="1" colspan="1">93.9&#x000b1;9.7</td><td align="left" rowspan="1" colspan="1">0.071</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x000a0;h</td><td align="left" rowspan="1" colspan="1">35&#x000b1;27</td><td align="left" rowspan="1" colspan="1">32&#x000b1;44</td><td align="left" rowspan="1" colspan="1">0.074</td></tr><tr><td align="left" colspan="4" rowspan="1">%IPA (collagen 2&#x000a0;&#x003bc;mol/L per &#x003bc;L)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2&#x000a0;h</td><td align="left" rowspan="1" colspan="1">99.7&#x000b1;0.72</td><td align="left" rowspan="1" colspan="1">99.6&#x000b1;0.96</td><td align="left" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6&#x000a0;h</td><td align="left" rowspan="1" colspan="1">97.5&#x000b1;7.9</td><td align="left" rowspan="1" colspan="1">98.5&#x000b1;4.2</td><td align="left" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">24&#x000a0;h</td><td align="left" rowspan="1" colspan="1">61.6&#x000b1;44</td><td align="left" rowspan="1" colspan="1">68&#x000b1;45</td><td align="left" rowspan="1" colspan="1">0.60</td></tr></tbody></table><table-wrap-foot><fn id="jah32244-note-0003"><p>IPA indicates inhibition of platelet reactivity; TRAP, thrombin receptor&#x02010;activating peptide.</p></fn></table-wrap-foot></table-wrap><p>IPA levels after stimulation with TRAP 10&#x000a0;&#x003bc;mol/L and TRAP 20&#x000a0;&#x003bc;mol/L were not significantly different between the groups at 2 and 6&#x000a0;hours (Figure&#x000a0;<xref rid="jah32244-fig-0004" ref-type="fig">4</xref>A and <xref rid="jah32244-fig-0004" ref-type="fig">4</xref>B; Table&#x000a0;<xref rid="jah32244-tbl-0003" ref-type="table-wrap">3</xref>). IPA levels with TRAP 10&#x000a0;&#x003bc;mol/L and TRAP 20&#x000a0;&#x003bc;mol/L in groups 1 and 2 were significantly lower at 24&#x000a0;hours as compared with those at 2 and 6&#x000a0;hours (Figure&#x000a0;<xref rid="jah32244-fig-0004" ref-type="fig">4</xref>A and <xref rid="jah32244-fig-0004" ref-type="fig">4</xref>B; Table&#x000a0;<xref rid="jah32244-tbl-0003" ref-type="table-wrap">3</xref>). IPA level with TRAP 20&#x000a0;&#x003bc;mol/L was significantly higher in group 2 as compared with that in group 1 at 6&#x000a0;hours (87.4&#x000b1;14% versus 74&#x000b1;17%; <italic>P</italic>&#x0003c;0.01, respectively; Figure&#x000a0;<xref rid="jah32244-fig-0004" ref-type="fig">4</xref>B).</p><fig fig-type="Figure" xml:lang="en" id="jah32244-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Inhibition of platelet aggregation (<styled-content style="fixed-case">IPA</styled-content>) with thrombin receptor activating peptide (<styled-content style="fixed-case">TRAP</styled-content>). A, <styled-content style="fixed-case">IPA</styled-content> with <styled-content style="fixed-case">TRAP</styled-content> 10&#x000a0;&#x003bc;mol/L after treatment with ticagrelor and eptifibatide (T+E) bolus vs ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion (T+E bolus and 2&#x02010;hour infusion). B, <styled-content style="fixed-case">IPA</styled-content> with <styled-content style="fixed-case">TRAP</styled-content> 20&#x000a0;&#x003bc;mol/L after treatment with ticagrelor and eptifibatide (T+E) bolus vs ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion (T+E bolus and 2&#x02010;hour infusion). In both (A and B), <styled-content style="fixed-case">IPA</styled-content> levels were significantly higher at 2 and 6&#x000a0;hours than 24&#x000a0;hours. <styled-content style="fixed-case">IPA</styled-content> level was significantly higher with T+E bolus and 2&#x02010;hour infusion than with T+E at 6&#x000a0;hours.</p></caption><graphic id="nlm-graphic-7" xlink:href="JAH3-6-e005562-g004"/></fig><p>IPA levels after stimulation with collagen 2&#x000a0;&#x003bc;mol/L/&#x003bc;L were not significantly different between the groups at 2 and 6&#x000a0;hours (Table&#x000a0;<xref rid="jah32244-tbl-0003" ref-type="table-wrap">3</xref>). IPA levels with collagen 2&#x000a0;&#x003bc;mol/L/&#x003bc;L in groups 1 and 2 were significantly lower at 24&#x000a0;hours than at 2 and 6&#x000a0;hours (Table&#x000a0;<xref rid="jah32244-tbl-0003" ref-type="table-wrap">3</xref>).</p></sec><sec id="jah32244-sec-0022"><title>High On&#x02010;Treatment Platelet Reactivity</title><p>As shown in Figure&#x000a0;<xref rid="jah32244-fig-0005" ref-type="fig">5</xref>A, the percentages of HPR stimulated with ADP 5&#x000a0;&#x003bc;mol/L were 89% and 79% before treatment in groups 1 and 2, respectively (<italic>P</italic>=0.46). HPR with ADP 5&#x000a0;&#x003bc;mol/L dropped to 0 at 2, 6, and 24&#x000a0;hours after treatment in both groups.</p><fig fig-type="Figure" xml:lang="en" id="jah32244-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Percentages of high on&#x02010;treatment platelet reactivity (<styled-content style="fixed-case">HPR</styled-content>). A, percentages of <styled-content style="fixed-case">HPR</styled-content> with <styled-content style="fixed-case">ADP</styled-content> 5&#x000a0;&#x003bc;mol/L using the cut point &#x0003e;46%. At baseline, percentages of <styled-content style="fixed-case">HPR</styled-content> were 89% and 79% (<italic>P</italic>=0.46). At 2, 6, and 24&#x000a0;hours, percentages of <styled-content style="fixed-case">HPR</styled-content> were 0, indicating that ticagrelor and eptifibatide bolus or infusion completely blocked platelet reactivity stimulated with <styled-content style="fixed-case">ADP</styled-content> 5&#x000a0;&#x003bc;mol/L. B, percentages of <styled-content style="fixed-case">HPR</styled-content> with <styled-content style="fixed-case">ADP</styled-content> 20&#x000a0;&#x003bc;mol/L using the cut point &#x0003e;59%. At baseline, percentages of <styled-content style="fixed-case">HPR</styled-content> were 82% and 76% (<italic>P</italic>=0.87). At 2, 6, and 24&#x000a0;hours, percentages of <styled-content style="fixed-case">HPR</styled-content> were 0, indicating that ticagrelor and eptifibatide bolus or infusion completely blocked platelet reactivity stimulated with <styled-content style="fixed-case">ADP</styled-content> 20&#x000a0;&#x003bc;mol/L.</p></caption><graphic id="nlm-graphic-9" xlink:href="JAH3-6-e005562-g005"/></fig><p>As shown in Figure&#x000a0;<xref rid="jah32244-fig-0005" ref-type="fig">5</xref>B, the percentages of HPR stimulated with ADP 20&#x000a0;&#x003bc;mol/L were 82% and 76% before treatment in groups 1 and 2, respectively (<italic>P</italic>=0.87). HPR with ADP 20&#x000a0;&#x003bc;mol/L dropped to 0 at 2, 6, and 24&#x000a0;hours after treatment in both groups.</p></sec><sec id="jah32244-sec-0023"><title>Outcomes</title><p>Details of in&#x02010;hospital and follow&#x02010;up outcomes are shown in Table&#x000a0;<xref rid="jah32244-tbl-0004" ref-type="table-wrap">4</xref>. One patient in group 2 developed gastrointestinal bleeding post&#x02010;PCI and required a blood transfusion. Incidence of PMI was not significantly different between the groups. Post&#x02010;PCI, hemoglobin level was significantly lower in group 2 as compared with baseline; however, no source of bleeding was identified. In group 1, 1 patient developed NSTE&#x02010;ACS as a result of in&#x02010;stent restenosis at 6&#x000a0;months. In group 2, there were 2 events; 1 patient died of progressive heart failure, and another patient developed in&#x02010;stent restenosis and required target lesion revascularization at 4 and 7&#x000a0;months, respectively.</p><table-wrap id="jah32244-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Outcomes</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor+Eptifibatide Bolus (n=35) Group 1</th><th align="left" valign="top" rowspan="1" colspan="1">Ticagrelor+Eptifibatide Bolus and Infusion (n=35) Group 2</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">In&#x02010;hospital events</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
Periprocedural myonecrosis, n (%)<break/>
(&#x0003e;5&#x000d7;99th percentiles or &#x0003e;20% increase in troponin levels)
</td><td align="left" rowspan="1" colspan="1">9 (26)</td><td align="left" rowspan="1" colspan="1">7 (20)</td><td align="left" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Baseline hemoglobin, g/dL</td><td align="left" rowspan="1" colspan="1">13.62&#x000b1;1.54</td><td align="left" rowspan="1" colspan="1">13.35&#x000b1;1.8</td><td align="left" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Postprocedure hemoglobin, g/dL</td><td align="left" rowspan="1" colspan="1">13.04&#x000b1;1.55</td><td align="left" rowspan="1" colspan="1">12.38&#x000b1;1.80<xref ref-type="fn" rid="jah32244-note-0004">a</xref>
</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bleeding (academic Research Consortium 3b)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Follow&#x02010;up events</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Duration of follow&#x02010;up, month</td><td align="left" rowspan="1" colspan="1">10&#x000b1;4.4</td><td align="left" rowspan="1" colspan="1">11&#x000b1;3.7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Death</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">TLR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NSTEMI</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Major adverse cardiovascular events, n</td><td align="left" rowspan="1" colspan="1">1 </td><td align="left" rowspan="1" colspan="1">2 </td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="jah32244-note-0004"><label>a</label><p>
<italic>P</italic>&#x0003c;0.05 compared with baseline hemoglobin. NSTEMI indicates non&#x02010;ST&#x02010;elevation myocardial infarction; TLR, target lesion revascularization.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="jah32244-sec-0024"><title>Discussion</title><p>To the best of our knowledge, the present study is the first to investigate the effects of ticagrelor and eptifibatide bolus versus ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion in patients with high&#x02010;risk NSTE&#x02010;ACS undergoing early PCI. The results of our study are summarized as follows:
<list list-type="order" id="jah32244-list-0003"><list-item><p>In P2Y<sub>12</sub>&#x02010;na&#x000ef;ve patients with high&#x02010;risk NSTE&#x02010;ACS undergoing early PCI, IPA with ticagrelor and eptifibatide bolus was maximal at 2&#x000a0;hours, the time frame in which most patients undergo PCI, suggesting that eptifibatide 2&#x02010;hour infusion is not needed.</p></list-item><list-item><p>Maximal inhibition of PA with ticagrelor and eptifibatide bolus is further supported by fact that platelet reactivity was below the cut points associated with ischemic risk.</p></list-item><list-item><p>Simultaneous inhibition of GPI and P2Y<sub>12</sub> receptors with eptifibatide and ticagrelor, respectively, provided a synergistic effect, such that eptifibatide, a strong TRAP&#x02010;induced platelet inhibitor, led to short&#x02010;term platelet inhibition during PCI, and ticagrelor, a strong ADP&#x02010;induced platelet inhibitor, induced sustained platelet inhibition up to 24 hours.</p></list-item><list-item><p>Ticagrelor and eptifibatide bolus versus 2&#x02010;hour infusion did not drop the post&#x02010;PCI hemoglobin level and may reduce bleeding complications.</p></list-item><list-item><p>PMI and cardiac events at 1 year were not significantly different between the groups.</p></list-item></list>
</p><p>Kim et&#x000a0;al<xref rid="jah32244-bib-0002" ref-type="ref">2</xref> reported that IPA with ticagrelor alone was inferior to tirofiban infusion at 2 hours in patients with NSTE&#x02010;ACS undergoing PCI. Angiolillo et&#x000a0;al<xref rid="jah32244-bib-0003" ref-type="ref">3</xref> showed that in P2Y<sub>12</sub>&#x02010;na&#x000ef;ve patients with unstable angina, the rate of HPR with ticagrelor was still high at 2 hours. Likewise, Valgimigli et&#x000a0;al<xref rid="jah32244-bib-0014" ref-type="ref">14</xref> showed that IPA with prasugrel and tirofiban bolus or 2&#x02010;hour infusion was significantly higher than prasugrel alone in patients with ST&#x02010;segment elevation myocardial infarction. Furthermore, the ATLANTIC trial<xref rid="jah32244-bib-0015" ref-type="ref">15</xref> demonstrated that the prehospital administration of ticagrelor did not improve pre&#x02010;PCI coronary reperfusion because maximal IPA with ticagrelor did not occur until 1&#x000a0;hour post&#x02010;PCI. Taken together, the above series indicate that even potent P2Y12 inhibitors (ie, prasugrel or ticagrelor) when administrated before PCI, do not achieve maximal platelet inhibition until the first 2 hours, the time frame in which most patients undergo PCI. Therefore, GPI is still needed to achieve maximal platelet inhibition quickly.</p><p>Notably, in the present study, there was no instance of HPR with ticagrelor and eptifibatide bolus. Mangiacapra et&#x000a0;al<xref rid="jah32244-bib-0016" ref-type="ref">16</xref> reported that HPR was an independent predictor of PMI after PCI. Likewise, Valgimgli et&#x000a0;al<xref rid="jah32244-bib-0017" ref-type="ref">17</xref> reported that treatment with tirofiban, in patients who had HPR with clopidogrel, resulted in a 40% reduction in the incidence of PMI compared with clopidogrel. Although it has been assumed that the use of potent P2Y<sub>12</sub> inhibitors would overcome the problem of HPR, recent data<xref rid="jah32244-bib-0004" ref-type="ref">4</xref> showed that HPR was still observed in a significant number of patients (25.2%) with prasugrel, a potent P2Y<sub>12</sub> inhibitor.</p><p>We demonstrated that the median time from admission to PCI was between 6 and 7&#x000a0;hours. A number of randomized trials<xref rid="jah32244-bib-0018" ref-type="ref">18</xref>, <xref rid="jah32244-bib-0019" ref-type="ref">19</xref> showed that early or immediate PCI reduced the event rates in high&#x02010;risk patients. Given the absence of robust data on the pretreatment strategy and the fact that the interval between admission and PCI has now shortened with modern practice, our study supports the concept of synergistic antiplatelet therapy with ticagrelor and eptifibatide bolus in high&#x02010;risk patients with NSTE&#x02010;ACS patients undergoing early PCI.</p><sec id="jah32244-sec-0025"><title>Clinical Implications</title><p>We showed that ticagrelor and eptifibatide bolus maximally inhibited PA and there was no instance of HPR, indicating that platelet reactivity was below the cut points associated with ischemic risk. Given that a number of studies<xref rid="jah32244-bib-0016" ref-type="ref">16</xref>, <xref rid="jah32244-bib-0017" ref-type="ref">17</xref> reported an association between HPR and increased PMI, the absence of HPR with the use of ticagrelor and eptifibatide bolus should reduce such events.</p><p>Current guidelines<xref rid="jah32244-bib-0005" ref-type="ref">5</xref> recommend a GPI infusion for 12 to 18&#x000a0;hours in high&#x02010;risk ACS patients. A GPI bolus or 2&#x02010;hour infusion with clopidogrel, as compared with a GPI infusion for 12 to 18&#x000a0;hours, decreased bleeding complications with no difference in outcomes.<xref rid="jah32244-bib-0007" ref-type="ref">7</xref>, <xref rid="jah32244-bib-0008" ref-type="ref">8</xref> Furthermore, Gurm et&#x000a0;al<xref rid="jah32244-bib-0020" ref-type="ref">20</xref> analyzed 21&#x000a0;296 patients; of these, 4511 were treated with eptifibatide bolus at the time of PCI and 16&#x000a0;785 received standard therapy (bolus plus infusion). They showed that patients receiving eptifibatide bolus only had significantly lower rates of bleeding events and blood transfusion with no difference in adverse events. Likewise, Kini et&#x000a0;al<xref rid="jah32244-bib-0007" ref-type="ref">7</xref> demonstrated that GPI bolus, compared with GPI bolus with standard infusion in 2699 patients undergoing PCI, reduced bleeding, duration of hospitalization, and cost with no difference in outcome. Furthermore, in the present study, there was no hemoglobin drop with ticagrelor and eptifibatide bolus in patients randomized to ticagrelor and eptifibatide bolus. In this respect, a randomized trial is warranted to investigate outcomes of high&#x02010;risk patients with NSTE&#x02010;ACS undergoing early PCI. Furthermore, randomized trials are warranted to investigate the safety and costs of ticagrelor and eptifibatide bolus versus cangrelor<xref rid="jah32244-bib-0021" ref-type="ref">21</xref> (a fast&#x02010;acting intravenous P2Y<sub>12</sub> inhibitor) and ticagrelor in high&#x02010;risk NSTE&#x02010;ACS patients undergoing early PCI.</p></sec><sec id="jah32244-sec-0026"><title>Limitations of the Study</title><p>In the present study, we used LTA to analyze platelet function. The most important advantage of LTA is that there is good correlation between the results and adverse events.<xref rid="jah32244-bib-0022" ref-type="ref">22</xref> There are several limitations of the study. First, a small patient population and therefore a small number of outcome events limit this study. Second, we did not compare the PD effect of ticagrelor and eptifibatide bolus or 2&#x02010;hour infusion with ticagrelor+unfractionated heparin/bivalirudin. In this respect, future studies are needed to compare the PD effect of ticagrelor and eptifibatide bolus with ticagrelor and unfractionated heparin/bivalirudin. Third, because clopidogrel and eptifibatide 18&#x02010; versus 2&#x02010;hour infusion increased bleeding,<xref rid="jah32244-bib-0008" ref-type="ref">8</xref> we did not randomize patients to ticagrelor and eptifibatide 18&#x02010; versus 2&#x02010;hour infusion. Fourth, because it has been demonstrated<xref rid="jah32244-bib-0023" ref-type="ref">23</xref> that the vasodilator&#x02010;stimulated phosphoprotein assay had minor differences as compared with the LTA measurements, we did not perform the vasodilator&#x02010;stimulated phosphoprotein assay to measure platelet reactivity index. Instead, multiple platelet function tests were performed in duplicates.</p></sec></sec><sec id="jah32244-sec-0027"><title>Conclusions</title><p>This is the first study to demonstrate that in P2Y<sub>12</sub>&#x02010;na&#x000ef;ve patients with high&#x02010;risk NSTE&#x02010;ACS undergoing early PCI, ticagrelor and eptifibatide bolus only, as compared with ticagrelor and eptifibatide bolus with 2&#x02010;hour infusion, maximally inhibited PA, which is further supported by platelet reactivity below the cut points of ischemic risk. This indicates that eptifibatide 2&#x02010;hour infusion is not needed.</p></sec><sec id="jah32244-sec-0029"><title>Sources of Funding</title><p>This study was supported by a grant from AstraZeneca. The collection, management, analysis, and interpretation of the data were performed by the UAB Cardiovascular Clinical trial Unite, Dr Marian, and Dr Leesar.</p></sec><sec id="jah32244-sec-0030"><title>Disclosures</title><p>Dr Leesar received an institution Grant from AstraZenca.</p></sec></body><back><ack id="jah32244-sec-0028"><title>Acknowledgments</title><p>The authors thank Jenny M. Phillips, MS, RD (AstraZeneca), for her contribution to the design of the study and Karen McFadden (AstraZeneca) for editing the manuscript. The authors also thank the staff of UAB cardiovascular trial unit (Joan Harshberger, RN; Valisia Croom, RN; Mehak Goel, PhD; and Megan Pickering, RN).</p></ack><ref-list content-type="cited-references" id="jah32244-bibl-0001"><title>References</title><ref id="jah32244-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah32244-cit-0001">
<string-name>
<surname>Steinhubl</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Talley</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Braden</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Tcheng</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Casterella</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Navetta</surname>
<given-names>FI</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Popma</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Dangas</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gallo</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sane</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Saucedo</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lincoff</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Theroux</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Holmes</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Teirstein</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Kereiakes</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Point&#x02010;of&#x02010;care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU&#x02010;Assessing Ultegra) multicenter study</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>:<fpage>2572</fpage>&#x02013;<lpage>2578</lpage>.<pub-id pub-id-type="pmid">11382726</pub-id></mixed-citation></ref><ref id="jah32244-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah32244-cit-0002">
<string-name>
<surname>Kim</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Jeong</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Sohn</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Chon</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>IS</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Noh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Chun</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Antiplatelet effect of ticagrelor compared to tirofiban in non&#x02010;ST&#x02010;segment elevation ACS patients undergoing PCI</article-title>. <source>Thromb Haemost</source>. <year>2016</year>;<volume>115</volume>:<fpage>2013</fpage>&#x02013;<lpage>2021</lpage>.</mixed-citation></ref><ref id="jah32244-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah32244-cit-0003">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Waksman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sweeny</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Raveendran</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Carlson</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mehran</surname>
<given-names>R</given-names>
</string-name>. <article-title>Effects of ticagrelor versus clopidogrel in troponin&#x02010;negative patients with low&#x02010;risk ACS undergoing ad hoc PCI</article-title>. <source>J Am Coll Cardiol</source>. <year>2016</year>;<volume>67</volume>:<fpage>603</fpage>&#x02013;<lpage>613</lpage>.<pub-id pub-id-type="pmid">26868683</pub-id></mixed-citation></ref><ref id="jah32244-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah32244-cit-0004">
<string-name>
<surname>Bonello</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pansieri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mancini</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bonello</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Maillard</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Barnay</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rossi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ait&#x02010;Mokhtar</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Jouve</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Collet</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Peyre</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Wittenberg</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>de Labriolle</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Camilleri</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cheneau</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cabassome</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dignat&#x02010;George</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Camoin&#x02010;Jau</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Paganelli</surname>
<given-names>F</given-names>
</string-name>. <article-title>High on&#x02010;treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>58</volume>:<fpage>467</fpage>&#x02013;<lpage>473</lpage>.<pub-id pub-id-type="pmid">21777742</pub-id></mixed-citation></ref><ref id="jah32244-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah32244-cit-0005">
<string-name>
<surname>Amsterdam</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Wenger</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Brindis</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Casey</surname>
<given-names>DE</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Ganiats</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Holmes</surname>
<given-names>DR</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Jaffe</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Jneid</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Kontos</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Levine</surname>
<given-names>GN</given-names>
</string-name>, <string-name>
<surname>Liebson</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Mukherjee</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Sabatine</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Smalling</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Zieman</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>2014 AHA/ACC guideline for the management of patients with non&#x02010;ST&#x02010;elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>64</volume>:<fpage>e139</fpage>&#x02013;<lpage>e228</lpage>.<pub-id pub-id-type="pmid">25260718</pub-id></mixed-citation></ref><ref id="jah32244-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah32244-cit-0006">
<string-name>
<surname>Boersma</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Simoons</surname>
<given-names>ML</given-names>
</string-name>. <article-title>Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta&#x02010;analysis of all major randomized clinical trials</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>359</volume>:<fpage>189</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">11812552</pub-id></mixed-citation></ref><ref id="jah32244-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah32244-cit-0007">
<string-name>
<surname>Kini</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>VH</given-names>
</string-name>, <string-name>
<surname>Krishnan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Mares</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Suleman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>SK</given-names>
</string-name>. <article-title>Bolus&#x02010;only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention</article-title>. <source>Am Heart J</source>. <year>2008</year>;<volume>156</volume>:<fpage>513</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">18760134</pub-id></mixed-citation></ref><ref id="jah32244-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah32244-cit-0008">
<string-name>
<surname>Fung</surname>
<given-names>AY</given-names>
</string-name>, <string-name>
<surname>Saw</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Starovoytov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Densem</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Jokhi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Walsh</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Humphries</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Aymong</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ricci</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Hamburger</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Carere</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Buller</surname>
<given-names>CE</given-names>
</string-name>. <article-title>Abbreviated infusion of eptifibatide after successful coronary intervention. The BRIEF&#x02010;PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>53</volume>:<fpage>837</fpage>&#x02013;<lpage>845</lpage>.<pub-id pub-id-type="pmid">19264239</pub-id></mixed-citation></ref><ref id="jah32244-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah32244-cit-0009">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Badimon</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Saucedo</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Frelinger</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Michelson</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Jakubowski</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ojeh</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Effron</surname>
<given-names>MB</given-names>
</string-name>. <article-title>A pharmacodynamic comparison of prasugrel vs. high&#x02010;dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease</article-title>. <source>Eur Heart J</source>. <year>2011</year>;<volume>32</volume>:<fpage>838</fpage>&#x02013;<lpage>846</lpage>.<pub-id pub-id-type="pmid">21252171</pub-id></mixed-citation></ref><ref id="jah32244-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah32244-cit-0010">
<string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Antonino</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Dichiara</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Suarez</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Singla</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tantry</surname>
<given-names>US</given-names>
</string-name>. <article-title>Platelet reactivity to adenosine diphosphate and long&#x02010;term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target</article-title>. <source>Platelets</source>. <year>2008</year>;<volume>19</volume>:<fpage>595</fpage>&#x02013;<lpage>604</lpage>.<pub-id pub-id-type="pmid">19012177</pub-id></mixed-citation></ref><ref id="jah32244-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah32244-cit-0011">
<string-name>
<surname>Thygesen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Alpert</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Jaffe</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Simoons</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Chaitman</surname>
<given-names>BR</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>. <article-title>Third universal definition of myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>60</volume>:<fpage>1581</fpage>&#x02013;<lpage>1598</lpage>.<pub-id pub-id-type="pmid">22958960</pub-id></mixed-citation></ref><ref id="jah32244-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah32244-cit-0012">
<string-name>
<surname>Mehran</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Caixeta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Eikelboom</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kaul</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wiviott</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Menon</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Nikolsky</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Serebruany</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Valgimigli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vranckx</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Taggart</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sabik</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Cutlip</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Krucoff</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Ohman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>H</given-names>
</string-name>. <article-title>Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>2736</fpage>&#x02013;<lpage>2747</lpage>.<pub-id pub-id-type="pmid">21670242</pub-id></mixed-citation></ref><ref id="jah32244-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah32244-cit-0013">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Jakubowski</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Ferreiro</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Tello&#x02010;Montoliu</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rollini</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Franchi</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ueno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Darlington</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Desai</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Moser</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Sugidachi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Guzman</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Bass</surname>
<given-names>TA</given-names>
</string-name>. <article-title>Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>64</volume>:<fpage>1005</fpage>&#x02013;<lpage>1014</lpage>.<pub-id pub-id-type="pmid">25190236</pub-id></mixed-citation></ref><ref id="jah32244-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah32244-cit-0014">
<string-name>
<surname>Valgimigli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tebaldi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Campo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gambetti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bristot</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Monti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Parrinello</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>R</given-names>
</string-name>. <article-title>Prasugrel versus tirofiban bolus with or without short post&#x02010;bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2012</year>;<volume>5</volume>:<fpage>268</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">22440491</pub-id></mixed-citation></ref><ref id="jah32244-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah32244-cit-0015">
<string-name>
<surname>Montalescot</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>van &#x02018;t Hof</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Lapostolle</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Silvain</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lassen</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Bolognese</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cantor</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Cequier</surname>
<given-names>A</given-names>
</string-name>. <article-title>Prehospital ticagrelor in ST&#x02010;segment elevation myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>1016</fpage>&#x02013;<lpage>1027</lpage>.<pub-id pub-id-type="pmid">25175921</pub-id></mixed-citation></ref><ref id="jah32244-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah32244-cit-0016">
<string-name>
<surname>Mangiacapra</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>De Bruyne</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Trana</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ntalianis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bartunek</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Heyndrickx</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Di Sciascio</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wijns</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Barbato</surname>
<given-names>E</given-names>
</string-name>. <article-title>High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2010</year>;<volume>3</volume>:<fpage>35</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">20129566</pub-id></mixed-citation></ref><ref id="jah32244-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah32244-cit-0017">
<string-name>
<surname>Valgimigli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Campo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>de Cesare</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Meliga</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Vranckx</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Furgieri</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Sabat&#x000e8;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hamon</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Repetto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Colangelo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brugaletta</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Parrinello</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Percoco</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>R</given-names>
</string-name>. <article-title>Intensifying platelet inhibition with tirofiban in poor&#x000a0;responders to aspirin, clopidogrel, or both agents undergoing elective&#x000a0;coronary intervention: results from the double&#x02010;blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>:<fpage>3215</fpage>&#x02013;<lpage>3222</lpage>.<pub-id pub-id-type="pmid">19528337</pub-id></mixed-citation></ref><ref id="jah32244-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah32244-cit-0018">
<string-name>
<surname>Mehta</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Granger</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Boden</surname>
<given-names>WE</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Bassand</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Faxon</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Afzal</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chrolavicius</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jolly</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>. <article-title>Early versus delayed invasive intervention in acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>:<fpage>2165</fpage>&#x02013;<lpage>2175</lpage>.<pub-id pub-id-type="pmid">19458363</pub-id></mixed-citation></ref><ref id="jah32244-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah32244-cit-0019">
<string-name>
<surname>Milosevic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vasiljevic&#x02010;Pokrajcic</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Milasinovic</surname>
<given-names>D</given-names>
</string-name>. <article-title>Immediate versus delayed invasive intervention for non&#x02010;ST&#x02010;segment elevation myocardial infarction</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2016</year>;<volume>9</volume>:<fpage>541</fpage>&#x02013;<lpage>549</lpage>.<pub-id pub-id-type="pmid">26777321</pub-id></mixed-citation></ref><ref id="jah32244-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah32244-cit-0020">
<string-name>
<surname>Gurm</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Hosman</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bates</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Share</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>BB</given-names>
</string-name>; <collab collab-type="authors">Blue Cross Blue Shield of Michigan Cardiovascular Consortium</collab>
. <article-title>Comparative effectiveness and safety of a catheterization laboratory&#x02010;only eptifibatide dosing strategy in patients undergoing percutaneous coronary intervention</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2015</year>;<volume>132</volume>:<fpage>1243</fpage>&#x02013;<lpage>1251</lpage>.</mixed-citation></ref><ref id="jah32244-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah32244-cit-0021">
<string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Price</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Saucedo</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Shaburishvili</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Prats</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials</article-title>. <source>J Thromb Thrombolysis</source>. <year>2012</year>;<volume>34</volume>:<fpage>44</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">22569899</pub-id></mixed-citation></ref><ref id="jah32244-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah32244-cit-0022">
<string-name>
<surname>Siller&#x02010;Matula</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Trenk</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schr&#x000f6;r</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gawaz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kristensen</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Storey</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>; <collab collab-type="authors">EPA (European Platelet Academy)</collab>
. <article-title>Response variability to P2Y12 receptor inhibitors: expectations and reality</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2013</year>;<volume>6</volume>:<fpage>1111</fpage>&#x02013;<lpage>1128</lpage>.<pub-id pub-id-type="pmid">24262612</pub-id></mixed-citation></ref><ref id="jah32244-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah32244-cit-0023">
<string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Butler</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Antonino</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Storey</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Nielsen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Sabe&#x02010;Affaki</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Husted</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kereiakes</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Henderson</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>DV</given-names>
</string-name>, <string-name>
<surname>Tantry</surname>
<given-names>US</given-names>
</string-name>. <article-title>Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>:<fpage>1188</fpage>&#x02013;<lpage>1199</lpage>.<pub-id pub-id-type="pmid">20194878</pub-id></mixed-citation></ref></ref-list></back></article>